Proficio Capital Partners LLC Takes Position in Illumina, Inc. $ILMN

Proficio Capital Partners LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 5,353 shares of the life sciences company’s stock, valued at approximately $941,000.

A number of other hedge funds also recently bought and sold shares of ILMN. Empowered Funds LLC boosted its position in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares during the period. Sivia Capital Partners LLC bought a new stake in shares of Illumina during the second quarter valued at approximately $621,000. CW Advisors LLC purchased a new position in shares of Illumina during the second quarter valued at approximately $275,000. Marshall Wace LLP grew its holdings in shares of Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after buying an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC boosted its holdings in shares of Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Activity

In related news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares of the company’s stock, valued at $4,067,600. This represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 1,874,458 shares of company stock worth $367,996,424. 2.90% of the stock is owned by insiders.

Illumina Price Performance

Shares of ILMN opened at $224.84 on Thursday. The firm has a fifty day moving average price of $191.66 and a 200 day moving average price of $154.42. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $227.70. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock has a market cap of $33.95 billion, a PE ratio of 41.95, a price-to-earnings-growth ratio of 3.17 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the firm posted $1.19 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of analyst reports. Royal Bank Of Canada upped their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. lifted their target price on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and set a $225.00 price target (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Finally, Canaccord Genuity Group raised their price target on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.